Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement
Status:
Recruiting
Trial end date:
2022-07-08
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind, vehicle controlled Phase 2 study with a 4-week open label
extension in adolescent and adult participants with atopic dermatitis and head and/or neck
involvement. It is intended to compare the efficacy and safety of ruxolitinib cream 1.5% BID
versus vehicle cream, then further evaluate ruxolitinib cream as maintenance during the open
label extension period.